BiotechTube

HTL0018318

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioavailability and Pharmacokinetics

Conditions

Bioavailability and Pharmacokinetics

Trial Timeline

Oct 1, 2016 → Jan 1, 2017

NCT ID
NCT02958696

About HTL0018318

HTL0018318 is a phase 1 stage product being developed by Nxera Pharma for Bioavailability and Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT02958696. Target conditions include Bioavailability and Pharmacokinetics.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02958696Phase 1Completed

Competing Products

20 competing products in Bioavailability and Pharmacokinetics

See all competitors
ProductCompanyStageHype Score
solifenacin succinate suspension + solifenacin succinate tabletAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
IpragliflozinAstellas PharmaPhase 1
33
HetrombopagJiangsu Hengrui MedicinePhase 1
33
ABT-450/r/ABT-267AbbViePhase 1
33
ABT-333AbbViePhase 1
33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2AstraZenecaPhase 1
33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orallyAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
selumetinib 75mg single doseAstraZenecaPhase 1
33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423AstraZenecaPhase 1
33
Fostamatinib + Fostamatinib + Fostamatinib + FostamatinibAstraZenecaPhase 1
33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcgAstraZenecaPhase 1
33
D1400147 + D14000136 + D14000137 + Epanova®AstraZenecaPhase 1
33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterAstraZenecaPhase 1
33
NKTR-118 + KetoconazoleAstraZenecaPhase 1
33
TEPEZZA + EDPAmgenPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavirPfizerPhase 1
32

Other Products from Nxera Pharma

Daridorexant + PlaceboPhase 3
76
HTL0018318 + PlaceboPhase 2
51
HTL0039732 Capsules + HTL0039732 Capsules and atezolizumab infusionPhase 1/2
40
HTL0009936 + HTL0009936 matching placeboPhase 1
32
HTL0018318 + Placebo oral capsulePhase 1
32